The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
62
The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
Genesis Research Services
Broadmeadow, New South Wales, Australia
ACTIVE_NOT_RECRUITINGResolve Pain
Buderim, Queensland, Australia
ACTIVE_NOT_RECRUITINGJessa Hasselt
Hasselt, Limburg, Belgium
Safety Evaluation
The incidence of serious procedure, device and/or stimulation-related adverse events.
Time frame: 12 weeks
Effectiveness Evaluation
Difference between randomization arms, in proportion of subjects with ≥ 30% reduction in the number of Monthly Migraine Days (MMD).
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AZ Sint Jan Brugge
Bruges, West Vlaanderen, Belgium
RECRUITINGAZ Delta
Roeselare, Belgium
RECRUITINGZAS Antwerpen, Campus Sint-Augustinus
Wilrijk, Belgium
RECRUITINGSt. Antonius Nieuwegein
Nieuwegein, Netherlands
RECRUITINGErasmus MC Rotterdam
Rotterdam, Netherlands
RECRUITING